Novo Nordisk reported DKK44.73B in Operating Expenses for its fiscal quarter ending in June of 2026.





Operating Expenses Change Date
Bausch Health Companies USD 2.08B 41M Jun/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Eli Lilly USD 10.52B 496M Jun/2026
GlaxoSmithKline GBP 5.8B 468M Jun/2026
Merck USD 15.77B 2.4B Jun/2026
Novartis USD 10.2B 912M Jun/2026
Novo Nordisk DKK 44.73B 7.52B Jun/2026
Novo Nordisk DKK 6.96B 30.25B Jun/2026
Pacira USD 180.54M 7.79M Jun/2026
Sanofi EUR 9.92B 607M Jun/2026
Supernus Pharmaceuticals USD 1.03B 45.58M Jun/2026